Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Annals of Oncology

• Publication date

  2003-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDG114PMID 12598340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.

  2002cited by this paper
• Clinical Prognostic Factors for Patients with Recurrent Head and Neck Cancer: Implications for Randomized Trials

  2001cited by this paper
• Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer.

  2001cited by this paper
• Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.

  1995cited by this paper
• An optimal three-stage design for phase II clinical trials.

  1994influential reference
• Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

  1992cited by this paper
• A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.

  1990cited by this paper
• A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer

  1985cited by this paper

• S16020 pyridocarbazole derivatives display high activity to lung cancer cells.

  2021cites this paper
• Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer

  2021cites this paper
• Evaluation of Interactions of Selected Olivacine Derivatives with DNA and Topoisomerase II

  2021cites this paper
• Bioactive Olivacine Derivatives—Potential Application in Cancer Therapy

  2021cites this paper
• Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.

  2020cites this paper
• Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.

  2018cites this paper
• Other Anticancer Drugs Targeting DNA and DNA-Associated Enzymes

  2015cites this paper
• Temporal changes in the efficacy of chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.

  2014cites this paper
• Palliative low dose fortnightly methotrexate in oral cancers: Experience at a rural cancer centre from India

  2014cites this paper
• Emerging Targets in the Bioactivity of Ellipticines and Derivatives

  2013cites this paper
• Antitumor carbazoles.

  2007cites this paper
• Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.

  2004cites this paper